STOCK TITAN

Mallinckrodt to Present at Cowen's 43rd Annual Health Care Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

Mallinckrodt plc (AMEX:MNK) announced that Siggi Olafsson, President and CEO, will present at Cowen's 43rd Annual Health Care Conference in Boston, MA, on March 7, 2023, at 2:50 p.m. Eastern Time. For those unable to attend in person, a webcast will be available, with a replay accessible after the event. Mallinckrodt, a global specialty pharmaceuticals company, focuses on areas such as autoimmune and rare diseases, including neurology and oncology. More details can be found on their website.

Positive
  • None.
Negative
  • None.

DUBLIN, Feb. 16, 2023 /PRNewswire/ -- Mallinckrodt plc (NYSE American: MNK), a global specialty pharmaceutical company, today announced that Siggi Olafsson, President and Chief Executive Officer, will present at Cowen's 43rd Annual Health Care Conference in Boston, MA on Tuesday, March 7, 2023 at 2:50 p.m. Eastern Time.

Individuals who cannot attend the meeting in person can find webcast information at: https://wsw.com/webcast/cowen132/mnk/1849260. A replay will also be available following the meeting.

ABOUT MALLINCKRODT 
Mallinckrodt is a global business consisting of multiple wholly owned subsidiaries that develop, manufacture, market and distribute specialty pharmaceutical products and therapies. The Company's Specialty Brands reportable segment's areas of focus include autoimmune and rare diseases in specialty areas like neurology, rheumatology, hepatology, nephrology, pulmonology, ophthalmology and oncology; immunotherapy and neonatal respiratory critical care therapies; analgesics; cultured skin substitutes and gastrointestinal products. Its Specialty Generics reportable segment includes specialty generic drugs and active pharmaceutical ingredients. To learn more about Mallinckrodt, visit www.mallinckrodt.com.

Mallinckrodt uses its website as a channel of distribution of important company information, such as press releases, investor presentations and other financial information. It also uses its website to expedite public access to time-critical information regarding the Company in advance of or in lieu of distributing a press release or a filing with the U.S. Securities and Exchange Commission (SEC) disclosing the same information. Therefore, investors should look to the Investor Relations page of the website for important and time-critical information. Visitors to the website can also register to receive automatic e-mail and other notifications alerting them when new information is made available on the Investor Relations page of the website.

CONTACTS

Investor Relations
Daniel Speciale
Global Corporate Controller & Chief Investor Relations Officer
314-654-3638 
daniel.speciale@mnk.com

Derek Belz
Vice President, Investor Relations
314-654-3950
derek.belz@mnk.com

Media
Michael Freitag / Aaron Palash / Aura Reinhard
Joele Frank, Wilkinson Brimmer Katcher
212-355-4449

Mallinckrodt, the "M" brand mark and the Mallinckrodt Pharmaceuticals logo are trademarks of a Mallinckrodt company. © 2023 02/23.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/mallinckrodt-to-present-at-cowens-43rd-annual-health-care-conference-301748832.html

SOURCE Mallinckrodt plc

FAQ

When is Mallinckrodt presenting at Cowen's Health Care Conference?

Mallinckrodt will present on March 7, 2023, at 2:50 p.m. Eastern Time.

Who is presenting on behalf of Mallinckrodt at the conference?

Siggi Olafsson, President and CEO, will present at the conference.

How can I watch the Mallinckrodt conference presentation?

You can watch the presentation via a webcast, available on their website.

What areas does Mallinckrodt specialize in?

Mallinckrodt specializes in autoimmune diseases, oncology, and other specialty areas.

What is the stock symbol for Mallinckrodt?

Mallinckrodt's stock symbol is MNK on the AMEX.

Mallinckrodt plc

NYSE:MNK

MNK Rankings

MNK Latest News

MNK Stock Data

4.52M
5.72M
10.09%
96.64%
13.46%
Drug Manufacturers - Specialty & Generic
Healthcare
Link
Ireland
Dublin